Transgenic mouse model for prostate cancer
US5907078A · kind A · utility
Inventors
Key dates
| Filing date | Mar 31, 1995 |
| Grant date | May 25, 1999 |
| Priority date | — |
| Expiry date | Mar 31, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/0331
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Several lines of transgenic mice have been generated using the prostate-specific rat probasin (PB) gene promoter to drive expression of the SV40 T antigen (Tag) coding region. Mice expressing high levels of the transgene specifically display progressive forms of prostatic cancer that histologically resemble human prostate cancer ranging from mild prostatic intraepithelial neoplasia (PIN) to large multinodular malignant adenocarcinoma with metastasis. Adenocarcinomas of the prostate have been detected as early as 10 weeks of age with extracapsular extension (ECE) and seminal vesicle invasion (SVI). Immunohistochemical analysis of tumor tissue has demonstrated that dorsolateral prostate-specific secretory proteins were confined to well differentiated ductal epithelial cells adjacent to, or within the poorly differentiated tumor mass. Prostate tumors in the mice also display elevated levels of nuclear p53, and a decreased heterogenous pattern of androgen receptor (AR) expression as observed in advanced human prostate cancer. The establishment of breeding lines of transgenic mice that reproducibly develop prostate cancer with metastasis provides a unique animal model system to study th…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.